These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26517325)

  • 1. Quality Assessment Errors and Study Misclassification Threaten Systematic Review Validity: Community Opioid Overdose Prevention and Naloxone Distribution Programs Review: Re: Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014 May-June;8(3): 153-163.
    Orkin AM; Bingham K; Buick JE; Klaiman M; Leece P; Kouyoumdjian F
    J Addict Med; 2015; 9(6):502-3. PubMed ID: 26517325
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "Quality Assessment Errors and Study Misclassification Threaten Systematic Review Validity: Community Opioid Overdose Prevention and Naloxone Distribution Programs Review".
    Winstanley EL; Clark A; Wilder CM
    J Addict Med; 2015; 9(6):503-4. PubMed ID: 26517326
    [No Abstract]   [Full Text] [Related]  

  • 3. A systematic review of community opioid overdose prevention and naloxone distribution programs.
    Clark AK; Wilder CM; Winstanley EL
    J Addict Med; 2014; 8(3):153-63. PubMed ID: 24874759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of naloxone for overdose prevention to chronic pain patients.
    Coe MA; Walsh SL
    Prev Med; 2015 Nov; 80():41-3. PubMed ID: 26024850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Awareness and Attitudes Toward Intranasal Naloxone Rescue for Opioid Overdose Prevention.
    Kirane H; Ketteringham M; Bereket S; Dima R; Basta A; Mendoza S; Hansen H
    J Subst Abuse Treat; 2016 Oct; 69():44-9. PubMed ID: 27568509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Take home naloxone for Ireland.
    Bury G
    Ir Med J; 2015 Mar; 108(3):70. PubMed ID: 25876295
    [No Abstract]   [Full Text] [Related]  

  • 7. Addressing co-occurring public health emergencies: The importance of naloxone distribution in the era of COVID-19.
    Collins AB; Ndoye CD; Arene-Morley D; Marshall BDL
    Int J Drug Policy; 2020 Sep; 83():102872. PubMed ID: 32713765
    [No Abstract]   [Full Text] [Related]  

  • 8. Naloxone distribution, trauma, and supporting community-based overdose responders.
    Shearer D; Fleming T; Fowler A; Boyd J; McNeil R
    Int J Drug Policy; 2019 Dec; 74():255-256. PubMed ID: 30527865
    [No Abstract]   [Full Text] [Related]  

  • 9. Butler, Kent Hospitals providing Narcan to overdose patients.
    R I Med J (2013); 2014 Sep; 97(9):55. PubMed ID: 25330544
    [No Abstract]   [Full Text] [Related]  

  • 10. Expanding access to naloxone in the United States.
    Doyon S; Aks SE; Schaeffer S; ; ;
    Clin Toxicol (Phila); 2014 Dec; 52(10):989-92. PubMed ID: 25283253
    [No Abstract]   [Full Text] [Related]  

  • 11. Identifying Patients for Overdose Prevention With ICD-9 Classification in the Emergency Department, Massachusetts, 2013-2014.
    Ellison J; Walley AY; Feldman JA; Bernstein E; Mitchell PM; Koppelman EA; Drainoni ML
    Public Health Rep; 2016 Sep; 131(5):671-675. PubMed ID: 28123207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal naloxone soon to become part of evolving clinical practice around opioid overdose prevention.
    Dietze P; Cantwell K
    Addiction; 2016 Apr; 111(4):584-6. PubMed ID: 26995168
    [No Abstract]   [Full Text] [Related]  

  • 13. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program.
    Oliva EM; Christopher MLD; Wells D; Bounthavong M; Harvey M; Himstreet J; Emmendorfer T; Valentino M; Franchi M; Goodman F; Trafton JA;
    J Am Pharm Assoc (2003); 2017; 57(2S):S168-S179.e4. PubMed ID: 28292502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nationwide pharmacy chain responds to the opioid epidemic.
    Shafer E; Bergeron N; Smith-Ray R; Robson C; O'Koren R
    J Am Pharm Assoc (2003); 2017; 57(2S):S123-S129. PubMed ID: 28163028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opiate addiction and overdose: experiences, attitudes, and appetite for community naloxone provision.
    Barry T; Klimas J; Tobin H; Egan M; Bury G
    Br J Gen Pract; 2017 Apr; 67(657):e267-e273. PubMed ID: 28246098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies and policies to address the opioid epidemic: A case study of Ohio.
    Penm J; MacKinnon NJ; Boone JM; Ciaccia A; McNamee C; Winstanley EL
    J Am Pharm Assoc (2003); 2017; 57(2S):S148-S153. PubMed ID: 28189539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid overdose prevention and naloxone distribution in Rhode Island.
    Yokell MA; Green TC; Bowman S; McKenzie M; Rich JD
    Med Health R I; 2011 Aug; 94(8):240-2. PubMed ID: 21913619
    [No Abstract]   [Full Text] [Related]  

  • 18. Opioid Overdose and Naloxone Kit Distribution: A Quality Assurance Educational Program in the Primary Care Setting.
    Lockett TL; Hickman KL; Fils-Guerrier BJ; Lomonaco M; Maye JP; Rossiter AG
    J Addict Nurs; 2018; 29(3):157-162. PubMed ID: 30180000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing take-home naloxone in an urban community pharmacy.
    Akers JL; Hansen RN; Oftebro RD
    J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.